Search

See sweet to C-suite: Carrie MacEwen

The business world tells us, “Know your why.” But increasingly, we live in a society where people think, “Why bother?” In this interview, David wants to know what makes Carrie MacEwen tick, and why she bothered to get involved locally,...

Addressing medical risk factors for diabetes and understanding the new systemic treatments

As global diabetes figures continue to rise, the importance of reducing the burden of macrovascular and microvascular complications of diabetes has never been so great. By 2025 it is estimated that five million people in the UK will have diabetes...

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

A career in uveitis

As he retires from clinical practice, the author looks back on his long career in uveitis and how care of these patients has changed dramatically since his days as an undergraduate. My trainees and fellows are often bored by my...

Do patient demographics influence AMD clinic attendance during COVID-19 lockdown?

The authors assess the impact of the COVID-19 pandemic on adherence to scheduled clinic appointments among age-related macular degeneration patients in a clinic in North Wales. The COVID-19 pandemic has significantly affected the population, affecting economic and social wellbeing, whilst...

Gene therapy for inherited retinal disease: the Manchester Ocular Gene Therapy Group MDT service

The authors describe the process set up in Manchester for the optimum delivery and assessment of a new gene therapy treatment for patients with RPE65 IRD. Inherited retinal dystrophies (IRDs) are the second commonest cause of severe visual impairment in...

Post-stroke visual impairment: how big is the problem, how do we identify it, what we can do about it, and why does it matter?

In the UK, 100,000 new strokes occur each year, with 1.3 million stroke survivors [1]. This article will focus on post-stroke visual impairment, discussing topics of how common it is, how it can be detected, possible management options and how...

Investigating the link between corneal clarity and statin use

Transparency is a vital attribute of the cornea, necessary in preserving healthy vision. Maintaining this requires the collective input of the various layers of the cornea. Mostly, the layers implicated in this are the corneal stroma and endothelium [1]. Our...